Nuvectis Pharma (NVCT) Gains from Sales and Divestitures (2024 - 2026)
Nuvectis Pharma's (NVCT) quarterly Gains from Sales and Divestitures came in at $190111.0 in Q1 2026, up 94.81% year-on-year from $97590.0 in Q1 2025, and down 7.39% quarter-over-quarter from $205290.0 in Q4 2025.
Nuvectis Pharma (NVCT) Gains from Sales and Divestitures (2024 - 2026) Analysis & Trends
Nuvectis Pharma has disclosed Gains from Sales and Divestitures across 3 years of filings, most recently posting $190111.0 for Q1 2026.
- Gains from Sales and Divestitures for Q1 2026 came in at $190111.0, up 94.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $190111.0 (up 94.81% YoY), and the FY2025 annual result was $205290.0, up 65.02% from the prior year.
- Gains from Sales and Divestitures came in at $190111.0 for Q1 2026 at Nuvectis Pharma, down from $205290.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $205290.0 in Q3 2025 to a low of $97590.0 in Q1 2025.
- The 3-year median for Gains from Sales and Divestitures is $156497.0 (2024), against an average of $153749.5.
- Across the five-year window, Gains from Sales and Divestitures soared 65.02% in 2025 and jumped 94.81% in 2026, its largest moves.
- Nuvectis Pharma's Gains from Sales and Divestitures stood at $124404.0 in 2024, then jumped by 65.02% to $205290.0 in 2025, then retreated by 7.39% to $190111.0 in 2026.
- The last three Gains from Sales and Divestitures figures came in at $190111.0 (Q1 2026), $205290.0 (Q4 2025), and $205290.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Nuvectis Pharma | 274.90 Mn | 274.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 190,111.00 |
| Mar 31, 2026 | 190,111.00 |
| Dec 31, 2025 | 205,290.00 |
| Dec 31, 2025 | 205,290.00 |
| Sep 30, 2025 | 205,290.00 |
| Sep 30, 2025 | 205,290.00 |
| Jun 30, 2025 | 188,590.00 |
| Jun 30, 2025 | 188,590.00 |
| Mar 31, 2025 | 97,590.00 |
| Mar 31, 2025 | 97,590.00 |
| Dec 31, 2024 | 124,404.00 |
| Dec 31, 2024 | 124,404.00 |
| Sep 30, 2024 | 115,304.00 |
| Sep 30, 2024 | 115,304.00 |
| Jun 30, 2024 | 103,417.00 |
| Jun 30, 2024 | 103,417.00 |